Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REGN 5093 M114

Next Previous
Drug Profile

REGN 5093 M114

Alternative Names: METxMET ADC - Regeneron Pharmaceuticals; METxMET-M114; REGN5093-M114

Latest Information Update: 21 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Maytansinoids
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer

Most Recent Events

  • 08 Apr 2022 Pharmacodynamics data from preclinical trials in Non-small cell lung cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 18 Oct 2021 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease, First-line therapy) in USA (IV) (NCT04982224)
  • 12 Aug 2021 Regeneron Pharmaceuticals plans a phase I/II trial in Non-small cell lung cancer (Late stage disease, In adults, In the elderly, First line therapy) (IV, Infusion), in August 2021 (NCT04982224) (Eudract2020-005065-14)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top